Search This Blog

Loading...

Articles

Sellers of Supple, a glucosamine and chondroitin liquid supplement, settle Federal Trade Commission charges on false advertising.
http://dlvr.it/MR9LWQ

Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research. Understanding cost differences can help guide informed discussions between patients and physicians when considering chemotherapy options.
http://dlvr.it/MR5Tny

Will astronauts traveling to Mars remember much of it? That's the question concerning scientists probing a phenomenon called "space brain." Scientists have found that exposure to highly energetic charged particles -- much like those found in the galactic cosmic rays that will bombard astronauts…
http://dlvr.it/MR5TcR

A well-known rheumatoid arthritis medication containing the active agent adalimumab, a therapeutic human monoclonal antibody, is also effective for treating non-infectious uveitis, a rare eye disease, report scientists.
http://dlvr.it/MR5TXZ

Children who develop asthma or allergies have an altered immune response to intestinal bacteria in the mucous membranes even when infants, according to a new study. The results also suggests that the mother's immune defense plays a role in the development of asthma and allergies in children.
http://dlvr.it/MR5TRN

A phase III trial of sunitinib has met its primary endpoint of disease-free survival for adjuvant treatment of high-risk renal cell carcinoma after nephrectomy, researchers report.
http://dlvr.it/MR5TLR

Neoadjuvant chemotherapy with an anthracycline plus ifosfamide was associated with significant survival gains in patients with soft tissue sarcoma of the trunk or extremities who are at high-risk of recurrence, in an interim analysis that led to the early discontinuation of a trial.
http://dlvr.it/MR5TC7

Cabozantinib significantly improves progression-free survival and response rate in patients with metastatic renal cell carcinoma compared to sunitinib, according to research.
http://dlvr.it/MR5T20

Researchers have known for more than 50 years that eating oats can lower cholesterol levels and thus reduce a person's risk of developing cardiovascular disease. Studies during that time have focused on the impact of oats on levels of LDL (or "lousy") cholesterol, which collects in the walls of…
http://dlvr.it/MR5SsY

MIT neuroscientist Earl Miller has changed the way we think about working memory — the brain's scratchpad.
http://dlvr.it/MR1QH3

"My guess is that even Medtronic is surprised." So said Jeffrey Brewer, the visionary tech entrepreneur who has been leading efforts to bring an artificial pancreas to market for a decade, in response to the unexpected news on Sept. 28 that the Food and Drug Administration approved one developed by…
http://dlvr.it/MQv4LJ

The addition of PD-1 antibody pembrolizumab to standard first-line chemotherapy for treatment-naïve advanced non-small-cell lung cancer significantly improves response rates and progression-free survival, researchers report.
http://dlvr.it/MQqHLB

Nintedanib improves progression-free survival but not overall survival in patients with metastatic colorectal cancer who are not responding to standard therapies, according to results of the phase III LUME-colon 1 trial.
http://dlvr.it/MQqHL7

The first phase III study of PD-L1 inhibitor atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, researchers report.
http://dlvr.it/MQqHKw

The first detailed biochemical characterization of a flavoenzyme involved in antibiotic resistance has now been revealed by scientists.
http://dlvr.it/MQqHKb

African-American and Hispanic men in the United States are less likely to receive therapy for prostate cancer compared to Caucasian men — even when they have more aggressive disease, according to new research.
http://dlvr.it/MQqHJp

The bacteria Pseudomonas aeruginosa can thrive in environments as different as the moist, warm tissue in our lungs, and the dry, nutrient-deprived surface of an office wall. Such adaptability makes it problematic in healthcare -- where it causes infections in cases of cystic fibrosis, cancer, HIV,…
http://dlvr.it/MQqHFx

Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 study.
http://dlvr.it/MQWPtQ

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression, according to the results of the phase III KEYNOTE-024 trial.
http://dlvr.it/MQWPqK

Nivolumab maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial.
http://dlvr.it/MQWPJ5

A nationwide study of head and neck cancers in France has revealed that the true burden of the disease is underestimated by at least one-third, and that head and neck cancers carry a very high risk of secondary primary cancers, according to research.
http://dlvr.it/MQVzsg

Seven out of ten patients with advanced cancer receive a palliative care consultation at ESMO Designated Centres of Integrated Oncology and Palliative Care, according to survey results.
http://dlvr.it/MQVzsV

The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from a trial. The trial met its primary endpoint, with niraparib considerably prolonging progression-free survival compared to placebo.
http://dlvr.it/MQVzsL

The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tumours were reported today at the ESMO 2016 Congress in Copenhagen. The novel compound uses messenger RNA…
http://dlvr.it/MQVzsG

The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer, researchers report.
http://dlvr.it/MQVzs8

No comments:

ScienceDaily: Health & Medicine News

ScienceDaily: Alternative Medicine News

आहार व आरोग्य

NCCAM Featured Content